Ensieh Lotfali

Dr. Ensieh Lotfali


Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2016 in Colloids and Surfaces B: Biointerfaces
Verified
Journal Article
Closed access
MMMaryam Moazeni
Maryam Moazeni
HAMIDREZA KELIDARIHAMIDREZA KELIDARI
HAMIDREZA KELIDARI
MSMajid Saeedi
Majid Saeedi
KMKatayoun Morteza-Semnani
Katayoun Morteza-Semnani
MNMojtaba Nabili
Mojtaba Nabili
Ali NokhodchiAli Nokhodchi
Ali Nokhodchi

1 January 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
SESaeed Emami
Saeed Emami
AFAlireza Foroumadi
Alireza Foroumadi
MFMehraban Falahati
Mehraban Falahati
ELEnsieh Lotfali
Ensieh Lotfali
SRSaeed Rajabalian
Saeed Rajabalian
ASAbbas Shafiee
Abbas Shafiee

1 June 2008 in Bioorganic & Medicinal Chemistry Letters
Verified
Journal Article
Closed access
AFAlireza Foroumadi
Alireza Foroumadi
ARArdeshir Rineh
Ardeshir Rineh
SESaeed Emami
Saeed Emami
FSFarideh Siavoshi
Farideh Siavoshi
SMSadegh Massarrat
Sadegh Massarrat
ASAbbas Shafiee
Abbas Shafiee

12 July 2023 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
KBKimia Basiji
Kimia Basiji
ASAzadeh Aghamohammadi Sendani
Azadeh Aghamohammadi Sendani
SGShaghayegh Baradaran Ghavami
Shaghayegh Baradaran Ghavami
MFMaryam Farmani
Maryam Farmani
NKNesa Kazemifard
Nesa Kazemifard
HAHamid Asadzadeh Aghdaei
Hamid Asadzadeh Aghdaei

16 September 2021 in ACS Omega
Verified
Journal Article
Open access
MSMohammad Shafiei
Mohammad Shafiei
HTHossein Toreyhi
Hossein Toreyhi
LFLoghman Firoozpour
Loghman Firoozpour
TATahmineh Akbarzadeh
Tahmineh Akbarzadeh
MAMohsen Amini
Mohsen Amini
AFAlireza Foroumadi
Alireza Foroumadi
Demand has arisen for developing new azole antifungal agents with the growth of the resistant rate of infective fungal species to current azole antifungals in recent years. Accordingly, the present study reports the synthesis of novel fluconazole (FLC) analogues bearing urea functionality that led to discovering new azole agents with promising antifungal activities. In particular, compounds 8b and 8c displayed broad-spectrum activity and superior in vitro antifungal capabilities compared to the standard drug FLC against sensitive and resistant Candida albicans (C. albicans). The highly active compounds 8b and 8c had potent antibiofilm properties against FLC-resistant C. albicans species. Additionally, these compounds exhibited very low toxicity for three mammalian cell lines and human red blood cells. Time-kill studies revealed that our synthesized compounds displayed a fungicidal mechanism toward fungal growth. Furthermore, a density functional theory (DFT) calculation, additional docking, and independent gradient model (IGM) studies were performed to analyze their structure–activity relationship (SAR) and to assess the molecular interactions in the related target protein. Finally, in vivo results represented a significant reduction in the tissue fungal burden and improvements in the survival rate in a mice model of systemic candidiasis along with in vitro and in silico studies, demonstrating the therapeutic efficiency of compounds 8b and 8c as novel leads for candidiasis drug discovery.

14 November 2018 in Archives of Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
AGAli Ghajari
Ali Ghajari
ELEnsieh Lotfali
Ensieh Lotfali
NANayeb Ali Ahmadi
Nayeb Ali Ahmadi
PFParvin Nazer Fassihi
Parvin Nazer Fassihi
NSNasrin Shahmohammadi
Nasrin Shahmohammadi
ZAZahra Arab-Mazar
Zahra Arab-Mazar
Archives of Clinical Infectious Diseases